Actively Recruiting

Phase Not Applicable
Age: 25Years - 45Years
All Genders
Healthy Volunteers
NCT06329544

High Fructose Diet, the Gut Microbiome, and Metabolic Health

Led by Icahn School of Medicine at Mount Sinai · Updated on 2025-12-17

30

Participants Needed

1

Research Sites

203 weeks

Total Duration

On this page

Sponsors

I

Icahn School of Medicine at Mount Sinai

Lead Sponsor

M

Metabolic Solutions Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

Americans commonly consume excess amounts of dietary fructose. Added fructose has been shown to have an adverse impact on metabolic health, including increased insulin resistance and type 2 diabetes (T2D) risk. However, the mechanisms that link dietary fructose and metabolic health are poorly understood. Malabsorption or incomplete metabolism of fructose in the small intestine is common in the population. Excess fructose reaches the colon where it may change the structure and function of the gut microbiome, alter bacterial metabolites and trigger inflammatory responses impacting T2D risk. To elucidate whether commonly consumed levels of dietary fructose influence metabolic outcomes through altering the gut microbiome, the research team will randomize 30 participants to a controlled cross-over dietary intervention, in which the participants will consume 12-day isocaloric, added fructose or glucose diets (25% of total calories) separated by a 10-day controlled diet washout period. The research team aims to: 1. Determine the relationships between high fructose consumption, the gut microbiome and metabolic risk. 2. Characterize the causal role(s) that fructose-induced alterations to the gut microbiome have on metabolic risk using a germ-free mouse model. The research team will measure 1) microbiota community structure and function via metagenomic sequencing of stool, 2) fecal metabolites via targeted and untargeted metabolomics, 3) anthropometrics, 4) insulin resistance, serum markers of T2D risk and inflammatory cytokines, 5) fecal microbial carbohydrate oxidation capacity and 6) liver fat via MRI elastography. The research team will use novel statistical approaches, including Distributed Lag Modeling, to understand the complex relationships between diet, the microbiome, metabolites and health outcomes. The research team will then conduct controlled dietary interventions and fecal microbiome transplantation studies in germ-free mice. Donor fecal samples from human participants in both the glucose and fructose arms of the clinical intervention will be transplanted into germ-free and colonized mice to establish a causal relationship between fructose-induced changes to the gut microbiome, liver fat and metabolic and inflammatory changes known to increase risk for T2D. The research team aims to comprehensively assess the structural and functional changes to the gut microbiome brought about by a high fructose diet. Determining the impact of excess fructose on the microbiome will help identify novel means by which fructose contributes to metabolic disease risk. In addition to identifying strategies to improve metabolic health in adults, data from this proposal could help inform targeted approaches to mitigate future disease risk in vulnerable populations that consume high levels of fructose, such as children.

CONDITIONS

Official Title

High Fructose Diet, the Gut Microbiome, and Metabolic Health

Who Can Participate

Age: 25Years - 45Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants must be confirmed as fructose malabsorbers by hydrogen breath test
Not Eligible

You will not qualify if you...

  • Use of probiotic, prebiotic, or synbiotic supplements
  • Consumption of more than 1 sugar-sweetened beverage per day
  • Antibiotic use within 3 months before enrollment or during the study
  • Vegetarian, vegan, or other restrictive diets
  • Food allergies
  • Alcohol intake exceeding 2 drinks per day
  • Diagnosis of major medical illness including type 1 or type 2 diabetes or eating disorder
  • Physical, mental, or cognitive disabilities preventing participation
  • Chronic use of medications affecting body weight, insulin resistance, or lipid profiles
  • Current smoking (more than 1 cigarette in the past week) or recreational drug use

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Mount Sinai Morningside

New York, New York, United States, 10025

Actively Recruiting

Loading map...

Research Team

R

Ryan Walker, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here